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See Article, pages 555–561The molecular characterization of hereditary diseases
has given rise to major advancements in the understand-
ing of pathophysiology in human disease. Among these
inborn defects of metabolism, Wilson’s disease (WD)
serves as an excellent model to study processes such as
copper metabolism, oxidative stress, neurodegeneration,
psychiatric disease, acute and chronic liver failure, as
well as hepatocarcinogenesis. WD results from a hepatic
copper transporter defect, which is responsible for trans-
locating copper into the bile [1,2]. It therefore represents
a genetic copper storage disease, whose clinical features
include acute, acute on chronic, and chronic liver dis-
ease, hemolysis, but also neuropsychiatric symptoms
too [3]. Since the ﬁrst description of WD patients by
Kinnear Wilson in 1912 as hepatolenticular degenera-
tion there have been many clinical reports highlighting
the phenotypical heterogeneity of this disease [4,5].
The ophthalmologists Kayser and Fleischer reported
already in 1902 and 1903, respectively, on corneal rings,
which were subsequently linked to WD [6,7]. These so
called Kayser-Fleischer rings illustrate a common char-
acteristic ﬁnding especially in WD patients presenting
with neurological disease. WD represents an orphan dis-
ease with a prevalence estimated to be about 1:30,000 to
1:100,000; it is more common in some isolated regions
[3,5].
The genetic trait was demonstrated to be autosomal
recessive inherited [8]. In 1985 Frydman et al. assigned
the gene for WD to chromosome 13 [9]. In 1991 the0168-8278/$34.00  2008 European Association for the Study of the Liver.
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as the underlying genetic cause (MIM# 277900)
[10,11]. This gene encodes a transmembrane copper-
transporting P-type ATPase (ATPase 7B) consisting
of 1465 amino acids, with six copper-binding domains,
eight transmembrane domains (Tm), a transduction
domain converting the energy of ATP hydrolysis to
cation transport, and a phosphorylation domain [12].
Since then, more than 400 mutations have been identi-
ﬁed, which have been reported in part by the Diane W.
Cox databank (http://www.medicalgenetics.med.ual-
berta.ca/wilson/index.php). Furthermore, the ATP7B
gene provides many additional SNPs, whose clinical
relevance has to be determined in the future. This
mutational diversity in WD underlines the genetic het-
erogeneity, thus limiting the introduction of simple and
rapid genetic testing for WD [13–22]. Furthermore, dis-
ease causing mutations on both alleles can only be
identiﬁed in about 80% of studied patients. Interest-
ingly, in children presenting with hepatic WD the
chance of identifying disease causing mutations is up
to 100%. Regional clustering of mutations has been
very well established [23–29]. This makes it possible
to use genetic diagnostics for regional screening
programs.
Aﬀected subjects within a family usually present with
a similar phenotype, but even within families phenotyp-
ical variety occurs [30–32]. In addition to the broad
spectrum of clinical manifestations, the age of onset
has been observed to range from 2 y.o. up to 71 y.o.
[33,34]. There are increasing reports on genotype-pheno-
type relationship in WD, which are very important to
deﬁne the role of genotyping [35–44]. The overall
impression from these reports is that the more striking
the ATP7B mutation is aﬀecting the gene productPublished by Elsevier B.V. All rights reserved.
450 H.H.-J. Schmidt / Journal of Hepatology 50 (2009) 449–452ATPase 7B, the earlier the onset of disease, the greater
the likelihood of the presentation of hepatic manifesta-
tion. However, variability even within the same families
carrying the same genotype exists. The substitution
mutation c.3207C>A (p.H1069Q) is identiﬁed more
commonly in adult patients with neuropsychiatric man-
ifestations, but can also occur in children with acute
liver failure [45]. However, very little is known with
regard to children.
Nicastro et al. report, in this issue of the Journal, on the
genotype–phenotype relation in Italian children present-
ingwithWD [46]. They retrospectively studied 58 patients
derived from 47 unrelated families. SSCP and direct
sequencing using a 2-step approach (1st: exon 5, 6, 8, 10,
12-19; 2nd: remaining exons in case of lack of identiﬁed
disease causingmutations on both alleles) revealed 34 dif-
ferent mutations accounting for 91.3% of studied WD
alleles. The majority of the children presented with hepa-
tic symptoms (86%). Kayser-Fleischer rings were detect-
able in 5 children. Mutations were grouped in
homozygotes and compound heterozygotes for missense
mutations versus homozygotes for nonsense and frame-
shift mutations. The latter group of patients presented
with lower serum ceruloplasmin and serum copper con-
centration at onset of disease compared to the group of
patients carrying missense mutations on both alleles.
Normalization of ALT serum concentration before and
under therapy (zinc, penicillamine) was used as criteria
for eﬀective treatment response, whichwas achievedmore
commonly in the group ofmissensemutations. The corre-
lation between the age at diagnosis and the urinary copper
excretion in this observational study highlights the prob-
lem of using this parameter in young children for diagnos-
ing WD. Taken together, the authors succeeded to
describe a large cohort of children presenting with WD
in detail and related the phenotype to the genotype.
The data provided substantiates that the genotype
plays a role to some extent in predicting the phenotype.
However, there is also the information on two aﬀected
brothers carrying the same genotype but presenting with
diﬀerent phenotype (neurological versus hepatic manifes-
tation). Homozygosity for c.3207C>A (p.H1069Q)
occurs more likely in adults with neurological features,
but here they were also detected in WD children. What
additional factors may inﬂuence the clinical presentation
of WD has still to be elucidated. Clearly, larger numbers
of studied patients, ideally carrying a homozygous geno-
type, are required to determine modiﬁer genes
(www.eurowilson.org). This is a common problem in all
association studies. Suggestedmodiﬁers just as the impact
of apoE genotype or the HFE genotype have not been
conﬁrmed so far [47,48]. The role of the prion protein
has also to be evaluated in larger cohorts [49,50]. The
canine copper toxicosis gene COMMD1 (MURR1)
seems to play no role in the clinical presentation of WD
[51,52]. Genes e.g. involved in metal transport, oxidationor mitochondria metabolism serve as candidates for
impacting WD. However, epigenetic regulation or non-
genetic factors may also be involved in the presentation
of WD.
Nicastro et al. detected mutations on both alleles in
almost all children. The high mutational yield is in con-
trast to many reports on genetics in adults. This phe-
nomenon may be explained, that the younger the age
of onset, the more likely mutations will be discovered.
However, SSCP and direct sequencing may also miss
mutations. Even more interestingly, treatment response
related to normalization of ALT was more likely to be
observed in the analyzed group carrying missense muta-
tions. The diﬀerentiation of missense mutations versus
frameshift/nonsense mutations seems to be very valu-
able and may relate to residual functional activity of
ATPase 7B in patients carrying missense mutations,
whereas patients carrying frameshift/nonsense muta-
tions will likely have no functional protein activity. Thus
genotype may in future enable us to predict treatment
eﬃcacy; surely this needs to be conﬁrmed.
Another important feature deriving from this study
is that children present primarily with hepatic manifes-
tations, however, neurological disease can occur. Fur-
thermore, diagnosis for WD is limited in children,
since characteristic ﬁndings such as Kayser-Fleischer
ring or pronounced increase of urinary copper excre-
tion is not usually helpful in this population. But this
makes the case: (i) WD can manifest as early as 2 years
of age, (ii) ﬁrst manifestation can be acute liver failure
and death, (iii) eﬀective treatment is available, (iv) pre-
liminary data imply that presymptomatic treatment
prevents onset of WD. Taken together, there is a need
for screening programs to minimize the disease burden
of WD. Genetic testing has limitations, but seems to be
the best tool to detect WD in children. Since this is a
rare disease, a genetic screening program can only be
justiﬁed once we develop simple, rapid, precise and
non-invasive tests at a low cost. At this point, the iden-
tiﬁcation of disease-causing mutations or informative
haplotypes in WD would allow the screening of rela-
tives, especially the screening of children. Thus genetic
screening should be recommended, although e.g. the
AASLD practice guidelines did not make clear recom-
mendations on this topic [53]. Since eﬀective treatment
is available, newborn screening or screening within the
ﬁrst two years of life seems to be most appropriate.
DNA chip technology may fulﬁl these criteria in the
future. These technologies have to overcome the
genetic heterogeneity in WD and mutational analysis
may diﬀer depending on the region. Current develop-
ments in genetic testing are promising for use in e.g.
newborn bloodspot analysis or genomic DNA derived
from buccal swaps [54,55]. Consequently, population-
based genetic screening programs for Wilson’s disease
may become a reality in the near future.
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